In this study, we examined 2269 individuals from two independent multicentre cohorts to first demonstrate the distributions of plasma NfL in CU individuals, the AD continuum and a broad range of neurodegenerative disorders, Down syndrome, and depression. Here, NEFL is linked to depressive symptom measurement.